fbpx
01 / 05
Human Trials of Artificial Wombs Could Start Soon

Nature | Health & Medical Care

Human Trials of Artificial Wombs Could Start Soon

“Researchers at CHOP are seeking approval for the first human clinical trials of the device they’ve been testing, named the Extra-uterine Environment for Newborn Development, or EXTEND. The team has emphasized that the technology is not intended — or able — to support development from conception to birth. Instead, the scientists hope that simulating some elements of a natural womb will increase survival and improve outcomes for extremely premature babies.”

From Nature.

Interesting Engineering | Health & Medical Care

Bio-Artificial Liver Approved for Clinical Trials in China

“A stem-cell-based artificial liver created by researchers at the Southern Medical University has now been approved for clinical trials by regulators in China. If the problems are cleared successfully, the novel approach could help millions of people battling liver failure worldwide.”

From Interesting Engineering.

Nature | Health & Medical Care

Life-Changing Cystic Fibrosis Treatment Wins $3-Million Prize

“The triple-drug combination Trikafta has given a new lease of life to 90% of people with cystic fibrosis, an inherited disorder that affects the lungs and other organs. Now, the trio of researchers who spearheaded its development has won one of this year’s US$3-million Breakthrough prizes — the most lucrative awards in science.”

From Nature.

Nature | Noncommunicable Disease

Super-Precise CRISPR Tool Enters US Clinical Trials

“A high-precision successor to CRISPR genome editing has reached a milestone: the technique, called base editing, has made its US debut in a clinical trial. The trial tests more complex genome edits than those performed in humans so far.

Trial organizers announced on 5 September that the first participant had been treated using immune cells with four base-edited genes, equipping the cells to better target and destroy tumours. The hope is that the approach can tame trial participants’ difficult-to-treat form of leukaemia and serve as a gateway to more complex edits in the future.”

From Nature.